NCT00470210View on ClinicalTrials.gov

Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Hepatitis CHIV Infections
Interventions
DRUG

Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week

Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week

DRUG

Ribavirin (Copegus®) 1600 mg/day

Ribavirin (Copegus®) 1600 mg/day

DRUG

Epoetin β (450 UI/kg/week)

Epoetin β (450 UI/kg/week)

Trial Locations (2)

08916

Hospital Germans Trias i Pujol, Badalona

08003

Hospital del Mar, Barcelona

All Listed Sponsors
collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

lead

Germans Trias i Pujol Hospital

OTHER

NCT00470210 - Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens | Biotech Hunter | Biotech Hunter